Ultragenyx Pharmaceutical (RARE) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$1.16

Estimate

-$0.75

Surprise

-54.4%

Score today

6.0/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

Ultragenyx Pharmaceutical (RARE) reported a wider loss than forecast — adjusted EPS of -$1.16 against the -$0.75 estimate (a 54.4% shortfall).

• Ultragenyx Pharmaceutical Q3 2026 Earnings Call Transcript — benzinga, 2026-11-03
• Ultragenyx Reports Third Quarter 2026 Financial Results and Announces Expense Reductions — fiscal.ai, 2026-11-03
• Ultragenyx Pharmaceutical Announces UX701 AAV9 Gene Therapy To Treat Wilson Disease Failed To Meet Criteria, Being Termi — benzinga, 2026-11-03

TrendMatrix currently rates RARE Sell at 6.0/10; no pre/post engine snapshot brackets this report.

1 of the last 4 quarters beat the estimate; this quarter's -54.4% surprise compares with a -15.1% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$16.63

Price target

$23.63

Stop

$15.47

Upside to target

+42.1%

Reward-to-risk

3.1:1

Model outputs from TrendMatrix’s engine as of 2026-11-04 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.64B

P/E (fwd)

73.7

52-week range

$12.73–$39.89

Off 52-week high

58.3%

RSI (14)

64

Volume vs avg

1.10×

Score today

6.0/10